Dexlansoprazole

CHEMBL1201863 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.4 g/mol

LogP

2.8

Phase

4

A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.

Peso Molecular

369,4000 g/mol

LogP

2,80

TPSA

87,10 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pain Management Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Infectious Disease Gastroesophageal Reflux Disease Lymphoma Type 2 Diabetes Breast Cancer Gout Chronic Pain Colorectal Cancer

Mecanismo de Ação

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1

InChI

InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

Molecular Formula

C16H14F3N3O2S

HBD / HBA

1 / 8

Ligações Rotacionáveis

5

Átomos Pesados

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A modified-release proton pump inhibitor and the R-enantiomer of lansoprazole that uses a dual delayed-release formulation to provide two separate drug-release phases, maintaining acid suppression for longer periods. It is used for gastroesophageal reflux disease and erosive esophagitis.

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Yes, Dexlansoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201863. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9578005. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Dexlansoprazole no PillFYI

Estrutura

Dados Rápidos

Fórmula: C16H14F3N3O2S
Sinônimos: 3

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.